APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-invasive Tumor Detection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-invasive Tumor Detection Market Outlook and Growth Opportunities 2026

3 May 2026185 pages

Choose your research edition.

Industry ResearchNon-invasive Tumor Detection Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-invasive Tumor Detection Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Non-invasive Tumor Detection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-invasive Tumor Detection Market Outlook and Growth Opportunities 2026185 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-invasive Tumor Detection Market Analysis and Forecast 2026-2032235 pages · $4,950 USD

Market perspective

The global Non-invasive Tumor Detection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-invasive Tumor Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-invasive Tumor Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-invasive Tumor Detection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-invasive Tumor Detection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-invasive Tumor Detection market include Datar Cancer Genetics, Nucleix, bioAffinity Technologies, miR Scientific, Nonacus, Natera and Penn Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Non-invasive Tumor Detection market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-invasive Tumor Detection and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-invasive Tumor Detection revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-invasive Tumor Detection market.

Non-invasive Tumor Detection Segment by Company

Datar Cancer Genetics

Nucleix

bioAffinity Technologies

miR Scientific

Nonacus

Natera

Penn Medicine

Non-invasive Tumor Detection Segment by Type

DNA

RNA

Non-invasive Tumor Detection Segment by Application

Prostate Cancer

Bladder Cancer

Pancreatic Cancer

Breast Cancer

Gastric Cancer

Others

Non-invasive Tumor Detection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Non-invasive Tumor Detection status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Non-invasive Tumor Detection key companies, revenue, market share, and recent developments.

3. To split the Non-invasive Tumor Detection breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Non-invasive Tumor Detection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-invasive Tumor Detection significant trends, drivers, influence factors in global and regions.

6. To analyze Non-invasive Tumor Detection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-invasive Tumor Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-invasive Tumor Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-invasive Tumor Detection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-invasive Tumor Detection industry.

Chapter 3: Detailed analysis of Non-invasive Tumor Detection company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Non-invasive Tumor Detection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Non-invasive Tumor Detection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-invasive Tumor Detection Industry Trends Table 2. Non-invasive Tumor Detection Industry Drivers Table 3. Non-invasive Tumor Detection Industry Opportunities and Challenges Table 4. Non-invasive Tumor Detection Industry Restraints Table 5. Global Non-invasive Tumor Detection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-invasive Tumor Detection Revenue Share by Company (2021-2026) Table 7. Global Non-invasive Tumor Detection Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Non-invasive Tumor Detection Key Company Manufacturing Base & Headquarters Table 9. Global Non-invasive Tumor Detection Company, Product Type & Application Table 10. Global Non-invasive Tumor Detection Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Non-invasive Tumor Detection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DNA Table 15. Significant Companies of RNA Table 16. Global Non-invasive Tumor Detection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Non-invasive Tumor Detection Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Non-invasive Tumor Detection Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Non-invasive Tumor Detection Sales Value Share by Type (2021-2026) Table 20. Global Non-invasive Tumor Detection Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Prostate Cancer Table 22. Significant Companies of Bladder Cancer Table 23. Significant Companies of Pancreatic Cancer Table 24. Significant Companies of Breast Cancer Table 25. Significant Companies of Gastric Cancer Table 26. Significant Companies of Others Table 27. Global Non-invasive Tumor Detection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Non-invasive Tumor Detection Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Non-invasive Tumor Detection Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Non-invasive Tumor Detection Sales Value Share by Application (2021-2026) Table 31. Global Non-invasive Tumor Detection Sales Value Share by Application (2027-2032) Table 32. Global Non-invasive Tumor Detection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Non-invasive Tumor Detection Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Non-invasive Tumor Detection Sales Value Share by Region (2021-2026) Table 35. Global Non-invasive Tumor Detection Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Non-invasive Tumor Detection Sales Value Share by Region (2027-2032) Table 37. Global Non-invasive Tumor Detection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Non-invasive Tumor Detection Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Non-invasive Tumor Detection Sales Value Market Share by Country (2021-2026) Table 40. Global Non-invasive Tumor Detection Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Non-invasive Tumor Detection Sales Value Market Share by Country (2027-2032) Table 42. Datar Cancer Genetics Company Information Table 43. Datar Cancer Genetics Business Overview Table 44. Datar Cancer Genetics Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Datar Cancer Genetics Non-invasive Tumor Detection Product Portfolio Table 46. Datar Cancer Genetics Recent Development Table 47. Nucleix Company Information Table 48. Nucleix Business Overview Table 49. Nucleix Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Nucleix Non-invasive Tumor Detection Product Portfolio Table 51. Nucleix Recent Development Table 52. bioAffinity Technologies Company Information Table 53. bioAffinity Technologies Business Overview Table 54. bioAffinity Technologies Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. bioAffinity Technologies Non-invasive Tumor Detection Product Portfolio Table 56. bioAffinity Technologies Recent Development Table 57. miR Scientific Company Information Table 58. miR Scientific Business Overview Table 59. miR Scientific Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. miR Scientific Non-invasive Tumor Detection Product Portfolio Table 61. miR Scientific Recent Development Table 62. Nonacus Company Information Table 63. Nonacus Business Overview Table 64. Nonacus Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Nonacus Non-invasive Tumor Detection Product Portfolio Table 66. Nonacus Recent Development Table 67. Natera Company Information Table 68. Natera Business Overview Table 69. Natera Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Natera Non-invasive Tumor Detection Product Portfolio Table 71. Natera Recent Development Table 72. Penn Medicine Company Information Table 73. Penn Medicine Business Overview Table 74. Penn Medicine Non-invasive Tumor Detection Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Penn Medicine Non-invasive Tumor Detection Product Portfolio Table 76. Penn Medicine Recent Development Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Non-invasive Tumor Detection Product Image Figure 2. Global Non-invasive Tumor Detection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-invasive Tumor Detection Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-invasive Tumor Detection Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DNA Image Figure 8. RNA Image Figure 9. Global Non-invasive Tumor Detection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Non-invasive Tumor Detection Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Non-invasive Tumor Detection Sales Value Share by Type (2021-2032) Figure 12. Prostate Cancer Image Figure 13. Bladder Cancer Image Figure 14. Pancreatic Cancer Image Figure 15. Breast Cancer Image Figure 16. Gastric Cancer Image Figure 17. Others Image Figure 18. Global Non-invasive Tumor Detection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Non-invasive Tumor Detection Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Non-invasive Tumor Detection Sales Value Share by Application (2021-2032) Figure 21. Global Non-invasive Tumor Detection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Non-invasive Tumor Detection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Non-invasive Tumor Detection Sales Value (2021-2032) & (US$ Million) Figure 24. North America Non-invasive Tumor Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Non-invasive Tumor Detection Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Non-invasive Tumor Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Non-invasive Tumor Detection Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Non-invasive Tumor Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Non-invasive Tumor Detection Sales Value (2021-2032) & (US$ Million) Figure 30. South America Non-invasive Tumor Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Non-invasive Tumor Detection Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Non-invasive Tumor Detection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • DNA
  • RNA
Applications
  • Prostate Cancer
  • Bladder Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
Companies covered
  • Datar Cancer Genetics
  • Nucleix
  • bioAffinity Technologies
  • miR Scientific
  • Nonacus
  • Natera
  • Penn Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-invasive Tumor Detection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-invasive Tumor Detection Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Non-invasive Tumor Detection Market Dynamics
  1. 2.1 Non-invasive Tumor Detection Industry Trends
  2. 2.2 Non-invasive Tumor Detection Industry Drivers
  3. 2.3 Non-invasive Tumor Detection Industry Opportunities and Challenges
  4. 2.4 Non-invasive Tumor Detection Industry Restraints
3 Non-invasive Tumor Detection Market by Company
  1. 3.1 Global Non-invasive Tumor Detection Company Revenue Ranking in 2025
  2. 3.2 Global Non-invasive Tumor Detection Revenue by Company (2021-2026)
  3. 3.3 Global Non-invasive Tumor Detection Company Ranking (2024-2026)
  4. 3.4 Global Non-invasive Tumor Detection Company Manufacturing Base and Headquarters
  5. 3.5 Global Non-invasive Tumor Detection Company Product Type and Application
  6. 3.6 Global Non-invasive Tumor Detection Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Non-invasive Tumor Detection Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Non-invasive Tumor Detection Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Non-invasive Tumor Detection Market by Type
  1. 4.1 Non-invasive Tumor Detection Type Introduction
  2. 4.1.1 DNA
  3. 4.1.2 RNA
  4. 4.2 Global Non-invasive Tumor Detection Sales Value by Type
  5. 4.2.1 Global Non-invasive Tumor Detection Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Non-invasive Tumor Detection Sales Value by Type (2021-2032)
  7. 4.2.3 Global Non-invasive Tumor Detection Sales Value Share by Type (2021-2032)
5 Non-invasive Tumor Detection Market by Application
  1. 5.1 Non-invasive Tumor Detection Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Bladder Cancer
  4. 5.1.3 Pancreatic Cancer
  5. 5.1.4 Breast Cancer
  6. 5.1.5 Gastric Cancer
  7. 5.1.6 Others
  8. 5.2 Global Non-invasive Tumor Detection Sales Value by Application
  9. 5.2.1 Global Non-invasive Tumor Detection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Non-invasive Tumor Detection Sales Value by Application (2021-2032)
  11. 5.2.3 Global Non-invasive Tumor Detection Sales Value Share by Application (2021-2032)
6 Non-invasive Tumor Detection Regional Value Analysis
  1. 6.1 Global Non-invasive Tumor Detection Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-invasive Tumor Detection Sales Value by Region (2021-2032)
  3. 6.2.1 Global Non-invasive Tumor Detection Sales Value by Region: 2021-2026
  4. 6.2.2 Global Non-invasive Tumor Detection Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-invasive Tumor Detection Sales Value (2021-2032)
  7. 6.3.2 North America Non-invasive Tumor Detection Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Non-invasive Tumor Detection Sales Value (2021-2032)
  10. 6.4.2 Europe Non-invasive Tumor Detection Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Non-invasive Tumor Detection Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Non-invasive Tumor Detection Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Non-invasive Tumor Detection Sales Value (2021-2032)
  16. 6.6.2 South America Non-invasive Tumor Detection Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Non-invasive Tumor Detection Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Non-invasive Tumor Detection Sales Value Share by Country, 2025 VS 2032
7 Non-invasive Tumor Detection Country-level Value Analysis
  1. 7.1 Global Non-invasive Tumor Detection Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-invasive Tumor Detection Sales Value by Country (2021-2032)
  3. 7.2.1 Global Non-invasive Tumor Detection Sales Value by Country (2021-2026)
  4. 7.2.2 Global Non-invasive Tumor Detection Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Non-invasive Tumor Detection Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Non-invasive Tumor Detection Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Non-invasive Tumor Detection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Datar Cancer Genetics
  2. 8.1.1 Datar Cancer Genetics Company Information
  3. 8.1.2 Datar Cancer Genetics Business Overview
  4. 8.1.3 Datar Cancer Genetics Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Datar Cancer Genetics Non-invasive Tumor Detection Product Portfolio
  6. 8.1.5 Datar Cancer Genetics Recent Developments
  7. 8.2 Nucleix
  8. 8.2.1 Nucleix Company Information
  9. 8.2.2 Nucleix Business Overview
  10. 8.2.3 Nucleix Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Nucleix Non-invasive Tumor Detection Product Portfolio
  12. 8.2.5 Nucleix Recent Developments
  13. 8.3 bioAffinity Technologies
  14. 8.3.1 bioAffinity Technologies Company Information
  15. 8.3.2 bioAffinity Technologies Business Overview
  16. 8.3.3 bioAffinity Technologies Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  17. 8.3.4 bioAffinity Technologies Non-invasive Tumor Detection Product Portfolio
  18. 8.3.5 bioAffinity Technologies Recent Developments
  19. 8.4 miR Scientific
  20. 8.4.1 miR Scientific Company Information
  21. 8.4.2 miR Scientific Business Overview
  22. 8.4.3 miR Scientific Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  23. 8.4.4 miR Scientific Non-invasive Tumor Detection Product Portfolio
  24. 8.4.5 miR Scientific Recent Developments
  25. 8.5 Nonacus
  26. 8.5.1 Nonacus Company Information
  27. 8.5.2 Nonacus Business Overview
  28. 8.5.3 Nonacus Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Nonacus Non-invasive Tumor Detection Product Portfolio
  30. 8.5.5 Nonacus Recent Developments
  31. 8.6 Natera
  32. 8.6.1 Natera Company Information
  33. 8.6.2 Natera Business Overview
  34. 8.6.3 Natera Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Natera Non-invasive Tumor Detection Product Portfolio
  36. 8.6.5 Natera Recent Developments
  37. 8.7 Penn Medicine
  38. 8.7.1 Penn Medicine Company Information
  39. 8.7.2 Penn Medicine Business Overview
  40. 8.7.3 Penn Medicine Non-invasive Tumor Detection Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Penn Medicine Non-invasive Tumor Detection Product Portfolio
  42. 8.7.5 Penn Medicine Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst